BR112018009980A2 - peptídeos e combinações de peptídeos para uso na imunoterapia contra o câncer de mama e outros cânceres - Google Patents
peptídeos e combinações de peptídeos para uso na imunoterapia contra o câncer de mama e outros cânceresInfo
- Publication number
- BR112018009980A2 BR112018009980A2 BR112018009980-5A BR112018009980A BR112018009980A2 BR 112018009980 A2 BR112018009980 A2 BR 112018009980A2 BR 112018009980 A BR112018009980 A BR 112018009980A BR 112018009980 A2 BR112018009980 A2 BR 112018009980A2
- Authority
- BR
- Brazil
- Prior art keywords
- peptides
- cells
- relates
- present
- tumor
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 7
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 5
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 238000009169 immunotherapy Methods 0.000 title abstract 2
- 206010006187 Breast cancer Diseases 0.000 title 1
- 208000026310 Breast neoplasm Diseases 0.000 title 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 abstract 1
- 108091008874 T cell receptors Proteins 0.000 abstract 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 230000005975 antitumor immune response Effects 0.000 abstract 1
- 238000002619 cancer immunotherapy Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
a presente invenção refere-se a peptídeos, proteínas, ácidos nucleicos e células para utilização em métodos de imunoterapia. mais especificamente, a presente invenção refere-se à imunoterapia do câncer. a presente invenção refere-se também a epítopos de peptídeos obtidos de células t associadas a tumores, isoladamente ou combinados com outros peptídeos associados a tumores, que podem, por exemplo, atuar como ingredientes farmacêuticos ativos de composições vacinais que estimulam respostas imunes antitumorais ou que estimulam células t ex vivo, que são depois transferidas a pacientes. peptídeos, quer ligados a moléculas do complexo principal de histocompatibilidade (mhc) ou peptídeos como tal, também podem ser alvos de anticorpos, de receptores de células t solúveis e de outras moléculas ligantes.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562270968P | 2015-12-22 | 2015-12-22 | |
| GBGB1522667.3A GB201522667D0 (en) | 2015-12-22 | 2015-12-22 | Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers |
| US62/270,968 | 2015-12-22 | ||
| GB1522667.3 | 2015-12-22 | ||
| PCT/EP2016/079059 WO2017108345A1 (en) | 2015-12-22 | 2016-11-29 | Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018009980A2 true BR112018009980A2 (pt) | 2018-11-13 |
Family
ID=55311455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018009980-5A BR112018009980A2 (pt) | 2015-12-22 | 2016-11-29 | peptídeos e combinações de peptídeos para uso na imunoterapia contra o câncer de mama e outros cânceres |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US10213499B2 (pt) |
| EP (2) | EP3394084B1 (pt) |
| JP (2) | JP2019510465A (pt) |
| KR (1) | KR20180089522A (pt) |
| CN (1) | CN108602855A (pt) |
| AU (2) | AU2016375806B2 (pt) |
| BR (1) | BR112018009980A2 (pt) |
| CA (1) | CA3009286A1 (pt) |
| CO (1) | CO2018003860A2 (pt) |
| CR (4) | CR20200555A (pt) |
| DK (1) | DK3394084T3 (pt) |
| EA (1) | EA201891465A1 (pt) |
| ES (1) | ES2867880T3 (pt) |
| GB (1) | GB201522667D0 (pt) |
| HU (1) | HUE054453T2 (pt) |
| LT (1) | LT3394084T (pt) |
| MA (3) | MA42020A1 (pt) |
| MD (1) | MD3394084T2 (pt) |
| MX (1) | MX2018005273A (pt) |
| PE (1) | PE20181800A1 (pt) |
| PL (1) | PL3394084T3 (pt) |
| PT (1) | PT3394084T (pt) |
| RS (1) | RS61787B1 (pt) |
| SG (2) | SG11201801384YA (pt) |
| SI (1) | SI3394084T1 (pt) |
| TW (1) | TWI655205B (pt) |
| WO (1) | WO2017108345A1 (pt) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201609193D0 (en) | 2016-05-25 | 2016-07-06 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers |
| JP7075125B2 (ja) | 2016-05-25 | 2022-05-25 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ |
| NZ754222A (en) | 2016-12-08 | 2022-02-25 | Immatics Biotechnologies Gmbh | T cell receptors with improved pairing |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| DK3428194T3 (da) | 2017-07-14 | 2021-11-15 | Immatics Biotechnologies Gmbh | Forbedret polypeptidmolekyle med dobbelt specificitet |
| DE102017127984B4 (de) | 2017-11-27 | 2019-12-05 | Immatics US, Inc. | Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen |
| AU2019218093A1 (en) | 2018-02-09 | 2020-09-10 | Immatics US, Inc. | Methods for manufacturing T cells |
| US20220120753A1 (en) * | 2018-09-21 | 2022-04-21 | The University Of Tokyo | Method for determining prognosis of cancer |
| WO2020191172A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
| AU2020283500A1 (en) | 2019-05-27 | 2022-01-27 | Immatics US, Inc. | Viral vectors and their use in adoptive cellular therapy |
| SG11202112561UA (en) | 2019-06-06 | 2021-12-30 | Immatics Biotechnologies Gmbh | Sorting with counter selection using sequence similar peptides |
| US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| AU2021225817A1 (en) | 2020-02-24 | 2022-10-20 | Immatics US, Inc. | Methods for expanding T cells for the treatment of cancer and related malignancies |
| DE102020106710A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| WO2022040631A1 (en) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
| CN111979323A (zh) * | 2020-08-28 | 2020-11-24 | 深圳裕策生物科技有限公司 | 用于预测肿瘤免疫治疗效果的生物标志物检测方法及*** |
| JP2024502034A (ja) | 2020-12-31 | 2024-01-17 | イマティクス ユーエス，アイエヌシー． | Ｃｄ８ポリペプチド、組成物、及びそれらの使用方法 |
| AU2022208746A1 (en) * | 2021-01-14 | 2023-08-03 | Loma Linda University | Methods for evaluation of early stage oral squamous cell carcinoma |
| CA3217739A1 (en) | 2021-05-05 | 2022-11-10 | Sebastian Bunk | Bma031 antigen binding polypeptides |
| CN113528436B (zh) * | 2021-08-04 | 2023-01-17 | 苏州大学 | 基于淋巴细胞的同源靶向性人工抗原呈递细胞及其构建和应用 |
| WO2023025851A1 (en) | 2021-08-24 | 2023-03-02 | Immatics US, Inc. | Selection of immune cells using peptide mhc complexes generated by conditional ligand exchange |
| US20230089392A1 (en) | 2021-09-20 | 2023-03-23 | Immatics US, Inc. | Monocyte depletion of t cells populations for t-cell therapy |
| US20230192886A1 (en) | 2021-11-08 | 2023-06-22 | Immatics Biotechnologies Gmbh | Adoptive cell therapy combination treatment and compositions thereof |
| CN114685641B (zh) * | 2022-02-25 | 2024-03-08 | 西安交通大学医学院第一附属医院 | 一种抑制brca1/bard1复合体结合的多肽及其应用和防治癌症的药物 |
| WO2023212691A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | DOMINANT NEGATIVE TGFβ RECEPTOR POLYPEPTIDES, CD8 POLYPEPTIDES, CELLS, COMPOSITIONS, AND METHODS OF USING THEREOF |
| WO2023212697A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| WO2023212655A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
| US20230355678A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4440859A (en) | 1977-05-27 | 1984-04-03 | The Regents Of The University Of California | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| NZ192465A (en) | 1978-12-22 | 1983-09-30 | Biogen Nv | Recombinant dna molecule comprising gene coding for polypeptide displaying hbv (hepatitis b virus) antigenicity usesthereof |
| US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| US4678751A (en) | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
| US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
| US4582800A (en) | 1982-07-12 | 1986-04-15 | Hoffmann-La Roche Inc. | Novel vectors and method for controlling interferon expression |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
| US4810648A (en) | 1986-01-08 | 1989-03-07 | Rhone Poulenc Agrochimie | Haloarylnitrile degrading gene, its use, and cells containing the gene |
| US4897445A (en) | 1986-06-27 | 1990-01-30 | The Administrators Of The Tulane Educational Fund | Method for synthesizing a peptide containing a non-peptide bond |
| RU2139092C1 (ru) | 1993-06-03 | 1999-10-10 | Терапьютик Антибодиз Инк. | Фрагменты антител в терапии |
| AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
| US6805861B2 (en) | 1996-01-17 | 2004-10-19 | Imperial College Innovations Limited | Immunotherapy using cytotoxic T lymphocytes (CTL) |
| US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| US20030211510A1 (en) * | 1999-06-30 | 2003-11-13 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US7211649B1 (en) * | 1999-07-02 | 2007-05-01 | Ana Mar Medical Ab | Cartilage intermediate layer protein |
| CA2494705A1 (en) | 1999-12-01 | 2001-06-07 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| WO2001041741A1 (en) * | 1999-12-13 | 2001-06-14 | Epimmune Inc. | Hla class i a2 tumor associated antigen peptides and vaccine compositions |
| WO2001046394A2 (en) * | 1999-12-21 | 2001-06-28 | Sugen, Inc. | Mammalian protein phosphatases |
| CA2404489A1 (en) | 2000-03-27 | 2001-10-04 | Technion Research And Development Foundation Ltd. | Single chain class i major histo-compatibility complexes, constructs encoding same and methods of generating same |
| US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
| CA2411470C (en) | 2000-06-05 | 2020-05-05 | Sunol Molecular Corporation | T cell receptor fusions and conjugates and methods of use thereof |
| JP4900884B2 (ja) | 2000-07-31 | 2012-03-21 | 株式会社グリーンペプタイド | 腫瘍抗原 |
| WO2002016939A2 (en) * | 2000-08-18 | 2002-02-28 | Eos Biotechnology, Inc. | Methods of diagnosis of cancer and screening for cancer modulators |
| US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
| EP1485075A4 (en) | 2002-02-20 | 2006-04-26 | Dyax Corp | MHC-PEPTIDE COMPLEX BINDING LIGANDS |
| AU2003271904B2 (en) | 2002-10-09 | 2009-03-05 | Adaptimmune Limited | Single chain recombinant T cell receptors |
| CA2505558C (en) | 2002-11-09 | 2013-07-02 | Avidex Limited | T cell receptor display |
| GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
| WO2005007090A2 (en) * | 2003-07-03 | 2005-01-27 | President And Fellows Of Harvard College | Inhibitors of the map kinase pathway |
| JP2008505648A (ja) | 2004-07-07 | 2008-02-28 | メタボレックス インコーポレーティッド | 糖尿病およびインスリン抵抗性の診断および治療の方法 |
| ATE461214T1 (de) | 2005-09-05 | 2010-04-15 | Immatics Biotechnologies Gmbh | Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden |
| US8957031B2 (en) | 2007-10-23 | 2015-02-17 | Regents Of The University Of Colorado, A Body Corporate | Competitive inhibitors of invariant chain expression and/or ectopic clip binding |
| KR100999043B1 (ko) * | 2007-12-04 | 2010-12-09 | 한국생명공학연구원 | 융합 단백질을 사용하지 않는 인간 단백질 타이로신탈인산화 효소의 활성 도메인 대량 생산 방법 |
| US20090263574A1 (en) | 2008-04-21 | 2009-10-22 | Quinn Daniel E | Method of restoring an article |
| EP2119726B2 (en) | 2008-05-14 | 2017-11-29 | Immatics Biotechnologies GmbH | Novel and powerful MHC-class II peptides derived from survivin and neurocan |
| GB201006360D0 (en) | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
| US20140170168A1 (en) | 2010-10-26 | 2014-06-19 | Yoram Reiter | Antibodies which bind soluble t-cell receptor ligands |
| WO2013057586A1 (en) | 2011-10-19 | 2013-04-25 | Oslo Universitetssykehus Hf | Compositions and methods for producing soluble t - cell receptors |
| US9561265B2 (en) * | 2012-07-10 | 2017-02-07 | Oncotherapy Science, Inc. | KIF20A epitope peptides for TH1 cells and vaccines containing the same |
| MX364370B (es) * | 2012-07-12 | 2019-04-24 | Persimmune Inc | Vacunas contra el cancer personalizadas y terapias de celulas inmunes adoptivas. |
| GB201214007D0 (en) * | 2012-08-07 | 2012-09-19 | Scancell Ltd | Anti-tumour immune responses to modified self-epitopes |
| EP2917388B1 (en) | 2012-11-08 | 2016-10-05 | Roche Diagnostics GmbH | Nucleic acids encoding chimeric polypeptides for library screening |
| EP2808392A1 (en) | 2013-05-28 | 2014-12-03 | Rheinische Friedrich-Wilhelms-Universität Bonn | Aptamers and use of the aptamers in the diagnosis and treatment of cancer |
| TWI819228B (zh) * | 2013-08-05 | 2023-10-21 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（八） |
| GB201319446D0 (en) * | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
-
2015
- 2015-12-22 GB GBGB1522667.3A patent/GB201522667D0/en not_active Ceased
-
2016
- 2016-11-29 EA EA201891465A patent/EA201891465A1/ru unknown
- 2016-11-29 SG SG11201801384YA patent/SG11201801384YA/en unknown
- 2016-11-29 EP EP16802063.4A patent/EP3394084B1/en active Active
- 2016-11-29 SI SI201631179T patent/SI3394084T1/sl unknown
- 2016-11-29 SG SG10202005950XA patent/SG10202005950XA/en unknown
- 2016-11-29 RS RS20210548A patent/RS61787B1/sr unknown
- 2016-11-29 MA MA42020A patent/MA42020A1/fr unknown
- 2016-11-29 PE PE2018000415A patent/PE20181800A1/es unknown
- 2016-11-29 CN CN201680075076.8A patent/CN108602855A/zh active Pending
- 2016-11-29 ES ES16802063T patent/ES2867880T3/es active Active
- 2016-11-29 EP EP21162594.2A patent/EP3875467A3/en active Pending
- 2016-11-29 WO PCT/EP2016/079059 patent/WO2017108345A1/en active Application Filing
- 2016-11-29 MD MDE20181036T patent/MD3394084T2/ro unknown
- 2016-11-29 HU HUE16802063A patent/HUE054453T2/hu unknown
- 2016-11-29 PT PT168020634T patent/PT3394084T/pt unknown
- 2016-11-29 DK DK16802063.4T patent/DK3394084T3/da active
- 2016-11-29 MA MA44101A patent/MA44101B1/fr unknown
- 2016-11-29 US US16/065,681 patent/US10213499B2/en active Active
- 2016-11-29 BR BR112018009980-5A patent/BR112018009980A2/pt active Search and Examination
- 2016-11-29 KR KR1020187020794A patent/KR20180089522A/ko not_active Application Discontinuation
- 2016-11-29 MA MA44693A patent/MA44693B1/fr unknown
- 2016-11-29 AU AU2016375806A patent/AU2016375806B2/en not_active Ceased
- 2016-11-29 CR CR20200555A patent/CR20200555A/es unknown
- 2016-11-29 LT LTEP16802063.4T patent/LT3394084T/lt unknown
- 2016-11-29 CR CR20180135A patent/CR20180135A/es unknown
- 2016-11-29 MX MX2018005273A patent/MX2018005273A/es unknown
- 2016-11-29 JP JP2018521114A patent/JP2019510465A/ja active Pending
- 2016-11-29 CR CR20200556A patent/CR20200556A/es unknown
- 2016-11-29 PL PL16802063T patent/PL3394084T3/pl unknown
- 2016-11-29 CR CR20200557A patent/CR20200557A/es unknown
- 2016-11-29 CA CA3009286A patent/CA3009286A1/en active Pending
- 2016-12-20 US US15/384,963 patent/US10064929B2/en active Active
- 2016-12-22 TW TW105142661A patent/TWI655205B/zh active
-
2018
- 2018-04-11 CO CONC2018/0003860A patent/CO2018003860A2/es unknown
-
2020
- 2020-12-16 AU AU2020289763A patent/AU2020289763B2/en active Active
-
2021
- 2021-04-29 JP JP2021076900A patent/JP2021121194A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018009980A2 (pt) | peptídeos e combinações de peptídeos para uso na imunoterapia contra o câncer de mama e outros cânceres | |
| BR112017027459A2 (pt) | peptídeos e combinações de peptídeos para uso na imunoterapia contra o câncer de ovário e outros cânceres | |
| BR112018001687A2 (pt) | peptídeos e combinações de peptídeos para uso na imunoterapia contra o câncer de próstata e outros cânceres | |
| BR112018015793A2 (pt) | peptídeos e combinações de peptídeos para uso na imunoterapia contra nhl e de outros cânceres | |
| BR112017028558A2 (pt) | peptídeos e combinações de peptídeos para uso na imunoterapia contra o câncer epitelial de ovário e outros cânceres | |
| BR112018008806A2 (pt) | peptídeos e combinações de peptídeos para uso na imunoterapia de diversos cânceres | |
| BR112017027639A2 (pt) | epítopos celulares e combinações de epítopos celulares para emprego na imunoterapia de mieloma e outros cânceres | |
| BR112017019804A2 (pt) | peptídeos e combinações de peptídeos e arcabouços para uso na imunoterapia contra o carcinoma de células renais (ccr) e outros cânceres | |
| BR112018003460A2 (pt) | peptídeos, combinações de peptídeos e suportes para emprego na imunoterapia de diversos cânceres | |
| BR112018016734A2 (pt) | peptídeos, combinações de peptí¬deos e medicamentos baseados em células para uso na imunoterapia contra o câncer de bexiga e outros cânceres | |
| BR112018007206A2 (pt) | peptídeos e combinações de peptídeos para uso em imunoterapia contra leucemia linfocítica crônica (cll) e outros cânceres | |
| BR112018017022A2 (pt) | peptídeos e combinações de peptídeos para uso em imunoterapia contra câncer de pulmão de células não pequenas e outros cânceres | |
| BR112017017289A2 (pt) | peptídeos e combinações de peptídeos para uso em imunoterapia contra diversos tumores | |
| BR112017017560A2 (pt) | peptídeos e combinações de peptídeos para uso em imunoterapia do câncer de pulmão, incluindo cpcnp e outros câncere | |
| BR112017019217A2 (pt) | peptídeos e combinações de peptídeos para uso em imunoterapia do câncer de pâncreas e outros cânceres | |
| BR112017023362A2 (pt) | peptídeos e combinação de peptídeos e arcabouços dos mesmos para uso na imunoterapia contra o carcinoma colorretal (crc) e outros cânceres | |
| BR112017028363A2 (pt) | peptídeos e combinações de peptídeos para uso na imunoterapia contra o câncer de esôfago e outros cânceres | |
| PH12018500864A1 (en) | Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers | |
| CR20180191A (es) | Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer microcítico de pulmón y otros tipos de cáncer | |
| CO2017012891A2 (es) | Péptidos y combinaciones de péptidos para la inmunoterapia contra el cáncer de ovario y otros tipos de cáncer | |
| BR112018015545A2 (pt) | tratamentos de câncer do útero | |
| BR112018068489A2 (pt) | peptídeos e combinações de peptídeos para uso em imunoterapia anticâncer | |
| BR112018073921A2 (pt) | peptídeos e combinações de peptídeos que servem como alvos e para uso na imunoterapia do câncer da vesícula biliar, do colangiocarcinoma e de outros cânceres | |
| BR112018070873A2 (pt) | imunoterapia contra melanoma e outros cânceres | |
| BR112019028070A2 (pt) | peptídeos e combinações de peptídeos para uso em imunoterapia contra câncer de pulmão, incluindo cpcnp, cppc e outros cânceres |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] |